TCT 2021: Intrepid TMVR: Results Show Improved NYHA Class at 30 Days | Dr Firas Zahr

Просмотров: 227   |   Загружено: 3 год.
icon
Radcliffe Cardiology
icon
3
icon
Скачать
iconПодробнее о видео
Watch the full video on Radcliffe Cardiology here:

In this video interview, Dr Firas Zahr (OHSU Hospital, Portland, OR, US) outlines the 30-day outcomes of the Intrepid TMVR Early Feasibility Study, originally presented at TCT 2021. This was a prospective multicenter trial, designed to study the feasibility of the Intrepid TMVR System. At 30 days, findings show favourable haemodynamics and an improved NYHA class in patients with mitral regurgitation.

Discussion points:
- The reason for the Intrepid TMVR study
- Study design and patient population
- Key Findings
- Further research

Recorded Remotely from Portland, 2021.
Interviewer: Jordan Rance

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.

Похожие видео

  © 2019-2021
  TCT 2021: Intrepid TMVR: Results Show Improved NYHA Class at 30 Days | Dr Firas Zahr - RusLar.Me